Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial

Boswood, Adrian; Häggström, Jens; G. Gordon, Sonya; Wess, Gerhard; L. Stepien, Rebecca; A. Oyama, Mark; W. Keene, Bruce; D. Bonagura, John; A. MacDonald, Kristin; Patteson, Mark; Smith, Sarah; R. Fox, Philip; Sanderson, Karen; Woolley, Richard; Szatmári, Viktor; Menaut, Pierre; M. Church, Whitney; Lynne O’Sullivan, M.; Jaudon, J.‐P.; Kresken, Jan‐Gerd; E. Rush, John; A. Barrett, Kirstie; L. Rosenthal, Steven; B. Saunders, Ashley; Ljungvall, Ingrid; Deinert, Michael; Bomassi, Éric; H. Estrada, Amara; Josefa Fernández del Palacio, María; Sydney Möise, N.; A. Abbott, Jonathan; Fujii, Yoko; W. Spier, Alan; W. Luethy, Michael; A. Santilli, Roberto; Uechi, Masami; Tidholm, Anna; Watson, Philip

doi:10.1111/jvim.14586

Public

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial

Published in Journal of Veterinary Internal Medicine • Sep 28, 2016

Authors:

Adrian Boswood

Jens Häggström

Sonya G. Gordon

Abstract

BACKGROUND: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. HYPOTHESIS/OBJECTIVES: Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with...

Subject

Medicine

Heart failure

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!